Streetbeat News

Stock Prices

BZFD

NVDA

RIVN

NVIDIA Corporation (NASDAQ:NVDA) shares surged 14.3% in pre-market trading after reporting Q4 financial results that exceeded expectations and provided strong Q1 revenue guidance. Other stocks also moved significantly in pre-market trading, with notable gainers including Agile Therapeutics, BuzzFeed, and Elevai Labs, among others. On the losing side, Draganfly, Synaptogenix, and Bel Fuse experienced significant drops following various announcements.

Portfolio Pulse from Avi Kapoor

February 22, 2024 | 12:55 pm

CQP

Cheniere Energy Partners (CQP) reported Q4 earnings of $1.42 per share, surpassing the $0.84 estimate, with sales of $2.69B also beating the $2.47B estimate. However, this represents a 26.8% decrease in earnings and a 43.11% decrease in sales from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

February 22, 2024 | 12:47 pm

TRN

Trinity Industries forecasts its 2024 EPS to be in the range of $1.30-$1.50, which is below the 2023 reported EPS of $1.43 and adjusted EPS of $1.38, and significantly lower than the consensus estimate of $1.95.

Portfolio Pulse from Benzinga Newsdesk

February 22, 2024 | 12:45 pm

NVDA

Nvidia CEO Jensen Huang predicts 'AI factories' will dominate every industry, leveraging Nvidia's 70% market share in AI chips. Nvidia is developing an 'operating system for AI,' which could become a significant business. The company's software services segment recently hit $1 billion in annualized revenue. Nvidia reported $22.1 billion in revenue for the fourth quarter, surpassing expectations. AI factories, powered by Nvidia's AI chips, transform data into valuable outputs, marking a new industry era.

Portfolio Pulse from Rounak Jain

February 22, 2024 | 12:44 pm

HRMY

Harmony Biosciences (NASDAQ:HRMY) reported Q4 2023 adjusted EPS of $0.73, surpassing the $0.48 estimate, marking a 52.08% beat but a 27.72% decrease from last year's $1.01. Sales reached $168.41M, slightly missing the $169.06M estimate by 0.38%, yet showing a 31.26% increase from the previous year.

Portfolio Pulse from Benzinga Newsdesk

February 22, 2024 | 12:40 pm

THRY

Thryv Holdings reported Q4 adjusted EPS of $0.32, missing the $0.37 estimate, and sales of $236.16M, beating the $231.79M estimate. This represents a 78.81% decrease in earnings and a 15.47% decrease in sales from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

February 22, 2024 | 12:37 pm

NTLA

Intellia Therapeutics (NTLA) reported Q4 losses of $(1.46) per share, missing the consensus estimate of $(1.45) by 0.69%. Year-over-year, this represents a 4.29% increase in losses. Quarterly sales were $(1.92 million), significantly below the $12.83 million estimate, marking a 114.12% decrease from the previous year.

Portfolio Pulse from Benzinga Newsdesk

February 22, 2024 | 12:36 pm

FCN

FTI Consulting (NYSE:FCN) reported Q4 adjusted EPS of $2.28, surpassing the $1.67 estimate, marking a 36.53% beat and a 50% increase from last year's $1.52. Sales reached $924.68M, exceeding the $840.40M estimate by 10.03% and showing a 19.40% increase from the previous year.

Portfolio Pulse from Benzinga Newsdesk

February 22, 2024 | 12:36 pm

MGPI

MGP Ingredients (NASDAQ:MGPI) reported Q4 adjusted EPS of $1.64, surpassing the $1.36 estimate, a 62.38% increase from last year. Sales reached $214.89M, beating the $205.39M estimate, marking a 12.51% increase from the previous year.

Portfolio Pulse from Benzinga Newsdesk

February 22, 2024 | 12:35 pm

WEN

Bernstein analyst Sara Senatore downgraded Wendy's (NASDAQ:WEN) from Outperform to Market Perform and reduced the price target from $24 to $20.

Portfolio Pulse from Benzinga Newsdesk

February 22, 2024 | 12:35 pm